The nation of Zimbabwe has turned down a major US health deal worth $367m (£272m) over five years due to Washington's request for confidential biological samples.
This move came to light after a official document from December was leaked, which showed President Emmerson Mnangagwa believed the agreement was "skewed".
An official representative has since stated that the United States was seeking genetic material for scientific study and commercial gain while refused to guarantee the resulting advantages from future treatments.
"We must now begin the difficult and regrettable process of winding down our support in Zimbabwe," said US ambassador to Zimbabwe Pamela Tremont in a statement.
The US Embassy said the United States had furnished over $1.9bn in health funding to Zimbabwe during the past two decades.
A physicians' group in Zimbabwe has urged more dialogue to reach a deal agreeable to both sides so the nation's vital HIV treatment initiative can be sustained.
Wider Context
This development follows a comparable situation in Kenya, where a court suspended a related deal with the US after concerns were filed about the security of Kenyans' health data.
Since returning to office last year, US President Donald Trump has drastically cut foreign aid and closed the key foreign aid agency.
The agency had managed assistance for the US government, but Trump argued its spending was "wasteful" and his administration was seeking government-to-government deals to boost openness and responsibility.
According to reports, Sixteen African countries have so far signed these new health pacts, constituting over $18.3bn in committed funds.
Details of the Declined Deal
The money for Zimbabwe was intended to supported "HIV/Aids treatment and prevention, tuberculosis, malaria, healthcare for mothers and children, and disease outbreak preparedness.
"It is our view this collaboration could have provided immense benefits for the people of Zimbabwe, particularly the 1.2 million currently receiving HIV treatment through US-supported initiatives," Tremont said.
However, government spokesperson Nick Mangwana argued the arrangement was "unequal".
"Zimbabwe was being asked to share its biological resources and data over an extended period, with no corresponding guarantee of benefiting from any medical innovations – such as new medicines or tests – that might result from that shared data," he stated.
"In essence, our country would supply the basic resources for medical research with no assurance that the resulting innovations would be available to our people should a new disease outbreak emerge."
National Interest and International Frameworks
He also pointed out that the US's withdrawal from the World Health Organization (WHO) and its push of one-on-one health agreements were undermining systems previously set up through the global organization.
Mangwana gave as an example its Pathogen Access and Benefit Sharing system created to manage potential pandemics.
"This system is designed to ensure that when a nation provides its information, the benefits – including medicines and cures – are shared equitably, not monopolised solely by those with the resources to develop them."
The government's concerns regarding the US deal "are not meant as anti-American sentiment," Mangwana stressed.
"We are open to further dialogue with our US partners on how subsequent co-operation might be structured in a way that honours the sovereignty and dignity of both nations."
Medical Community Reaction
A leading public health body expressed it acknowledged the government's concerns, but urged that negotiations need to persist given that much of the nation's Aids initiatives were funded by international support.
"In cases where technical issues exist, such as those involving information security or implementation frameworks, these can frequently be resolved through technical clarification and mutually agreed protections," it said.
The halted deal highlights the continuing tensions between receiving vital foreign assistance and safeguarding a country's data in an ever more data-driven world.